Bril Vera
Continuum (Minneap Minn). 2014 Jun;20(3 Neurology of Systemic Disease):531-44. doi: 10.1212/01.CON.0000450964.30710.a0.
Diabetes mellitus has become a modern global epidemic, with steadily increasing prevalence rates related to lifestyle such that 27% of individuals aged 65 years or older have diabetes mellitus, 95% of whom have type 2. This article reviews the effects of diabetes mellitus on the neuromuscular system.
Diabetes mellitus leads to diverse forms of peripheral neuropathy as the major neuromuscular complication. Both focal and diffuse types of neuropathy can develop, with the most common form being diabetic sensorimotor polyneuropathy. Small fibers are damaged early in the development of diabetic sensorimotor polyneuropathy and are not assessed by nerve conduction studies. Small fiber damage occurs even in the prediabetes stage. No disease-modifying therapy for diabetic sensorimotor polyneuropathy is available at this time, but this complication can be limited in patients who have type 1 diabetes mellitus with strict glycemic control; the same outcome is not clearly observed in patients who have type 2 diabetes mellitus. Recently, the evidence base for symptomatic treatments of painful diabetic sensorimotor polyneuropathy underwent systematic review. Effective evidence-based treatments include some anticonvulsants (eg, pregabalin, gabapentin), antidepressants (eg, amitriptyline, duloxetine), opioids (eg, morphine sulfate, oxycodone), capsaicin cream, and transcutaneous electrical nerve stimulation.
This article reviews the increasing prevalence of diabetes mellitus and diabetic sensorimotor polyneuropathy and discusses recent consensus opinion on the objective confirmation needed for the diagnosis in the clinical research setting. The evidence from clinical trials shows that intensive glycemic control reduces prevalence of diabetic sensorimotor polyneuropathy in patients with type 1 diabetes mellitus, but variable outcomes are observed in patients with type 2 diabetes mellitus. Finally, despite the lack of disease-modifying treatment, effective evidence-based therapy can control painful symptoms of diabetic sensorimotor polyneuropathy.
糖尿病已成为一种现代全球性流行病,其患病率因生活方式的影响而稳步上升,65岁及以上人群中有27%患有糖尿病,其中95%为2型糖尿病。本文综述糖尿病对神经肌肉系统的影响。
糖尿病会引发多种形式的周围神经病变,这是主要的神经肌肉并发症。局灶性和弥漫性神经病变均可发生,最常见的形式是糖尿病性感觉运动性多发神经病变。在糖尿病性感觉运动性多发神经病变发展早期,小纤维就会受损,而神经传导研究无法对此进行评估。即使在糖尿病前期阶段,小纤维也会受损。目前尚无针对糖尿病性感觉运动性多发神经病变的疾病改善疗法,但对于1型糖尿病患者,严格控制血糖可限制该并发症;在2型糖尿病患者中,尚未明确观察到同样的结果。最近,对疼痛性糖尿病性感觉运动性多发神经病变的对症治疗证据基础进行了系统评价。有效的循证治疗包括一些抗惊厥药(如普瑞巴林、加巴喷丁)、抗抑郁药(如阿米替林、度洛西汀)、阿片类药物(如硫酸吗啡、羟考酮)、辣椒素乳膏和经皮电刺激神经疗法。
本文综述了糖尿病和糖尿病性感觉运动性多发神经病变患病率的上升情况,并讨论了临床研究中诊断所需客观确认的近期共识意见。临床试验证据表明,强化血糖控制可降低1型糖尿病患者糖尿病性感觉运动性多发神经病变的患病率,但2型糖尿病患者的结果各异。最后,尽管缺乏疾病改善治疗,但有效的循证疗法可控制糖尿病性感觉运动性多发神经病变的疼痛症状。